147 related articles for article (PubMed ID: 38656744)
1. [Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer].
Wikström P; Bergh A; Josefsson A; Thysell E; Welén K
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38656744
[TBL] [Abstract][Full Text] [Related]
2. [Molecular biomarkers and prognostic factors for prostate cancer].
Kretschmer A; Tolkach Y; Ellinger J; Kristiansen G
Urologe A; 2017 Jul; 56(7):933-944. PubMed ID: 28573413
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of PCS and PAM50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract][Full Text] [Related]
5. Integrative molecular profiling of routine clinical prostate cancer specimens.
Grasso CS; Cani AK; Hovelson DH; Quist MJ; Douville NJ; Yadati V; Amin AM; Nelson PS; Betz BL; Liu CJ; Knudsen KE; Cooney KA; Feng FY; McDaniel AS; Tomlins SA
Ann Oncol; 2015 Jun; 26(6):1110-1118. PubMed ID: 25735316
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
7. Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Reichert ZR; Kasputis T; Nallandhighal S; Abusamra SM; Kasputis A; Haruray S; Wang Y; Williams S; Singhal U; Alva A; Cackowski FC; Caram MEV; Palmbos PL; Yentz SE; Smith DC; Alumkal JJ; Morgan TM
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008431
[TBL] [Abstract][Full Text] [Related]
8. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
9. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
10. The Value of Phenotypic Precision Medicine in Prostate Cancer.
Hawkey NM; Broderick A; George DJ; Sartor O; Armstrong AJ
Oncologist; 2023 Feb; 28(2):93-104. PubMed ID: 36200788
[TBL] [Abstract][Full Text] [Related]
11. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
[TBL] [Abstract][Full Text] [Related]
12. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.
Armstrong AJ; Li X; Tucker M; Li S; Mu XJ; Eng KW; Sboner A; Rubin M; Gerstein M
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):786-793. PubMed ID: 33568750
[TBL] [Abstract][Full Text] [Related]
13. Advancing precision medicine for prostate cancer through genomics.
Roychowdhury S; Chinnaiyan AM
J Clin Oncol; 2013 May; 31(15):1866-73. PubMed ID: 23589550
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.
Clark E; Morton M; Sharma S; Fisher H; Howel D; Walker J; Wood R; Hancock H; Maier R; Marshall J; Bahl A; Crabb S; Jain S; Pedley I; Jones R; Staffurth J; Heer R
BMJ Open; 2019 Dec; 9(12):e034708. PubMed ID: 31857319
[TBL] [Abstract][Full Text] [Related]
15. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
16. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
[TBL] [Abstract][Full Text] [Related]
17. Genomic tests to guide prostate cancer management following diagnosis.
Colicchia M; Morlacco A; Cheville JC; Karnes RJ
Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
[TBL] [Abstract][Full Text] [Related]
18. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T; Moris L; Gevaert T; Tosco L; Smeets E; Fishbane N; Liu Y; Helsen C; Margrave J; Buerki C; Davicioni E; Van Poppel H; Everaerts W; Weinmann S; Den R; Davis J; Schaeffer E; Karnes RJ; Claessens F; Joniau S
Eur Urol Oncol; 2019 Sep; 2(5):589-596. PubMed ID: 31411980
[TBL] [Abstract][Full Text] [Related]
19. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.
Crippa A; De Laere B; Discacciati A; Larsson B; Connor JT; Gabriel EE; Thellenberg C; Jänes E; Enblad G; Ullen A; Hjälm-Eriksson M; Oldenburg J; Ost P; Lindberg J; Eklund M; Grönberg H
Trials; 2020 Jun; 21(1):579. PubMed ID: 32586393
[TBL] [Abstract][Full Text] [Related]
20. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB; Liu Y; Hakansson A; Zhao X; Proudfoot JA; Ho J; Zhang JH; Li EV; Karnes RJ; Den RB; Kishan AU; Reiter RE; Hamid AA; Ross AE; Tran PT; Davicioni E; Spratt DE; Attard G; Lotan TL; Lee Kiang Chua M; Sweeney CJ; Schaeffer EM
Cancer; 2023 Jul; 129(14):2169-2178. PubMed ID: 37060201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
